14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs HNST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, The Honest Company, Inc. (HNST) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HNST carries 36.7/100 (SELL) at $4.88 (43.5x Forward P/E, 2.4% operating margin).
Defensive Composite Rating Caution: Although HNST compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HNST (36.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Household & Personal Products value chain with $547.1M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment40.0% of Rev ($134M)
90D Engineering Disclosures0 Published
Investor FAQ SKIN vs HNST Key Questions & Quantitative Answers
As of Nov 16, 2026, The Honest Company, Inc. (HNST) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas HNST carries 36.7/100 (SELL) at $4.88 (43.5x Forward P/E, 2.4% operating margin). Defensive Composite Rating Caution: Although HNST compares more favorably head-to-head, both SKIN (34.1/100 SELL) and HNST (36.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SKIN leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with HNST at -8.6% YoY revenue growth and N/A YoY earnings growth on $334M TTM revenue (42.4% gross margin, 2.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while HNST shifted +54.2%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($134M) (0 disclosures) for HNST.
HNST screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas HNST trades at 43.5x Forward P/E, 7.3x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus HNST (34.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, HNST carries 68.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.46x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.